Anti-Human PD-1 mAb, Seafrom (CAT#: STEM-CT-0009-ZJF)

The Anti-Human PD-1 mAb manufactured by Seafrom is suitable for blocking the PD-1/PD-L1 pathway to enhance T cell activity in cell therapy.
PD-1, primarily expressed in activated T cells and B cells, functions to inhibit cell activation. This is a normal self-regulating mechanism of the immune system, as excessive activation of T/B cells can lead to autoimmune diseases. Therefore, PD-1 serves as a protective mechanism in our body. However, the tumor microenvironment can induce infiltrating T cells to overexpress the PD-1 molecule, while tumor cells also overexpress the ligands of PD-1, PD-L1, and PD-L2. This leads to the continuous activation of the PD-1 pathway in the tumor microenvironment, resulting in the suppression of T cell function, making them unable to effectively kill tumor cells. PD-1 antibodies can block this pathway, partially restoring T cell function, allowing them to continue attacking tumor cells. As a result, anti-human PD-1 monoclonal antibodies have an "inhibitory" effect on expanded T cells in vitro, significantly enhancing the immune cells' ability to kill tumor cells.
Storage: Store at 2~8°C with a shelf life of 24 months. If needed for aliquoting, aliquots can be stored at -20°C for 6 months or at -80°C for 12 months, avoiding repeated freeze-thaw cycles.

Expression Host: CHO Cells
Purity: >90%, analyzed by SDS-PAGE
Endotoxin Level: <0.1 EU/µg
Activity: Measured through binding capacity in functional ELISA with a linear range of 10-100 ng/mL
Purification Method: Protein A affinity chromatography
Appearance: Colorless transparent liquid

High purity, activity, and stability
High batch to batch consistency
Gmp production management standards

Anti-Human CD137 mAb, Seafrom
Anti-Human HER-2 mAb, Seafrom
Humanized Anti-Human CD3/CD19 Bispecific Antibody, Seafrom
Recombinant Human IL-1β Protein, Seafrom